LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study
about
LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell modelsLongitudinal measures of proteostasis in live neurons: features that determine fate in models of neurodegenerative diseaseFBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophyPathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis.Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice.Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus.MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit functionDivergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.The Role of Astrocyte Dysfunction in Parkinson's Disease Pathogenesis.Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.The screening of the 3'UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease.
P2860
Q24304959-D23794ED-F73C-4654-872F-4C1600A1AFA5Q26865220-F0AFD482-91DC-4043-BD6F-5D4E739FB7FDQ28117902-03DDFDE5-800A-478D-A8F2-54DA041CD413Q31028020-6E54349D-A3C4-4C28-BD46-5E3A66D89236Q33797449-5BCF147B-402A-4ED5-8DE1-1C09F58106C6Q34723024-73392201-D788-41B2-8F6E-73577757C3ACQ34962651-55133D65-530F-46BA-A097-9281EE2D6586Q36525872-C4751A1D-6B55-49C2-8AED-5559C9A3FDF6Q36581417-A9B4402E-D503-4933-8DEE-92DCF51EF2DEQ37119983-44B47F83-E97D-4537-A133-CE82443A67FFQ39136594-D14ADFA5-9D7A-464F-A1A1-0B4B56C2B058Q39319763-C14343F4-7E65-4F2C-AE54-11661C87B7DDQ47281413-4136CC62-0D31-4515-9CF5-4816A6726FC8Q48308135-322ED36C-C518-4D32-BBC3-D9B4238A7662
P2860
LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
LRRK2 expression in idiopathic ...... logical and quantitative study
@ast
LRRK2 expression in idiopathic ...... logical and quantitative study
@en
LRRK2 expression in idiopathic ...... logical and quantitative study
@en-gb
LRRK2 expression in idiopathic ...... logical and quantitative study
@nl
type
label
LRRK2 expression in idiopathic ...... logical and quantitative study
@ast
LRRK2 expression in idiopathic ...... logical and quantitative study
@en
LRRK2 expression in idiopathic ...... logical and quantitative study
@en-gb
LRRK2 expression in idiopathic ...... logical and quantitative study
@nl
prefLabel
LRRK2 expression in idiopathic ...... logical and quantitative study
@ast
LRRK2 expression in idiopathic ...... logical and quantitative study
@en
LRRK2 expression in idiopathic ...... logical and quantitative study
@en-gb
LRRK2 expression in idiopathic ...... logical and quantitative study
@nl
P2093
P2860
P50
P921
P1476
LRRK2 expression in idiopathic ...... logical and quantitative study
@en
P2093
A E Kingsbury
J L Holton
R Bandopadhyay
S S O'Sullivan
P2860
P304
P356
10.1111/J.1365-2990.2011.01187.X
P407
P577
2011-12-01T00:00:00Z